Short interest for Minerva Neurosciences gives investors a sense of the degree to which investors are betting on the decline of Minerva Neurosciences's stock. Short interest data is updated every two weeks.

Minerva Neurosciences Stock (NASDAQ:NERV), Short Interest Report

Minerva Neurosciences

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Hims & Hers Health, Inc. Class A Common Stock

HIMS

JANX

NERV

NRXP

TWKS

VKTX

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday.

The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41. The S&amp;P 500 also rose, gaining, 0.04% to 5,071.40.

Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings

Movers

Trading Ideas

AHCO

ALPP

AULT

BBAI

BEAM

BIOR

BLUE

CARG

CDXS

CLDI

CLVT

CXAI

DNLI

DORM

EGIO

ELWS

FEAM

HSII

IFBD

LGND

LUNR

MICS

NVCR

PEGY

PRGO

PRIM

PRST

PTLO

PUBM

PYXS

SOUN

STGW

STRL

TBIO

TMDX

TREE

WDAY

WETG

Shares of  Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Biotech

Health Care

General

Minerva Neurosciences faces FDA challenges for roluperidone in schizophrenia treatment. Understand the clinical deficiencies and potential paths forward. Cash position at December 31, 2023, around $41.0 million.

Regulatory Setback For Minerva Neurosciences&#39; Schizophrenia Treatment Candidate, FDA Asks For More Data

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences Inc

NERVGEN PHARMA CORP by NervGen Pharma Corp.

NervGen Pharma Corp

NerveNetwork

Nervos Network

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) with a Neutral and lowers the price target from $11 to $7.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $7

Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.20) by 5.83 percent. This is a 13.74 percent increase over losses of $(1.31) per share from the same period last year.

Earnings Beats

Minerva Neurosciences Q1 2024 GAAP EPS $(1.13) Beats $(1.20) Estimate; Cash, Cash Equivalents And Restricted Cash Of $34.9M

Minerva Neurosciences On April 10, Got Notice From Nasdaq That Company Was Not In Compliance With Nasdaq's Listing Rule

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday.
The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41. The S&amp;P 500 also rose, gaining, 0.04% to 5,071.40.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37331804/wall-streets-most-accurate-analysts-views-on-3-risk-off-stocks-with-over-5-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Risk Off Stocks With Over 5% Dividend Yields </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Utilities shares rose by 1.2% on Tuesday.
In trading on Tuesday, energy shares fell by 0.4%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
The J.M. Smucker Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sjm#NYSE">SJM</a>) posted better-than-expected earnings for its fourth quarter on Tuesday.
The company reported third-quarter adjusted earnings per share of $2.48, beating the analyst consensus of $2.27. J.M. Smucker registered quarterly revenues of $2.229 billion, marginally beating the consensus estimate of $2.220 billion.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares shot up 191% to $44.00 after the company announced updated clinical data for both of its clinical programs.
Shares of Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) got a boost, surging 32% to $13.50 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.
Viking Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares were also up, gaining 94% to $74.79 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>) shares dropped 57% to $2.95 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
Shares of Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) were down 31% to $3.1785 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.
NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) was down, falling 33% to $0.2851 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 1.6% to $78.81 while gold traded up 0.1% at $2,041.60.
Silver traded fell 0.3% to $22.46 on Tuesday while copper rose 0.4% to $3.85.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed mixed today. The eurozone&rsquo;s STOXX 600 fell 0.18%, London&rsquo;s FTSE 100 fell 0.02% while Spain&rsquo;s IBEX 35 Index fell 0.24% The German DAX gained 0.76% French CAC 40 rose 0.23% while Italy&rsquo;s FTSE MIB Index rose 0.46%.
Bank lending to households in the Eurozone rose by 0.3% year-over-year to EUR 6.870 trillion for January. The consumer confidence indicator in France declined to 89 in February versus around two-year high level of 91 in the prior month. The GfK Consumer Climate Indicator for Germany climbed to a reading of -29.0 heading into March compared to February&#39;s level of 29.6.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 0.01%, Hong Kong&rsquo;s Hang Seng Index climbing 0.94%, China&rsquo;s Shanghai Composite Index surging 1.29% and India&rsquo;s S&amp;P BSE Sensex gaining 0.4%.
Hong Kong recorded a trade surplus of $3.6 billion in January compared to a year-ago deficit of $25.4 billion. The annual inflation rate in Japan slowed to 2.2% in January compared to 2.6% in the earlier month.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. durable goods orders fell by 6.1% month-over-month in January compared to a 0.3% decline in December.
The FHFA house price index rose 0.1% in December following a 0.4% increase in November.
The S&amp;P CoreLogic Case-Shiller 20-city home price index climbed by 6.1% year-over-year in December.
The Dallas Fed general business activity index for Texas&rsquo; service sector rose to -3.9 in February from -9.3 in the previous month
Now Read This: <a href="https://www.benzinga.com/news/24/02/37333478/roku-crocs-and-2-other-stocks-insiders-are-selling"> Roku, Crocs And 2 Other Stocks Insiders Are Selling </a>
&nbsp;

Shares of Helix Energy Solutions Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlx#NYSE">HLX</a>) fell sharply during Tuesday&rsquo;s session following weak earnings.
Helix Energy posted adjusted earnings of 6 cents per share, missing market estimates of 10 cents per share. The company&rsquo;s quarterly sales came in at $335.16 million versus expectations of $315.60 million.
Helix Energy Solutions shares dipped 11% to $9.13 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares jumped 145% to $37.00 after the company announced updated clinical data for both of its clinical programs.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) surged 72% to $0.5657.</li>
<li>Viking Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares jumped 71.2% to $65.88 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.</li>
<li>CXApp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxai#NASDAQ">CXAI</a>) gained 67% to $2.58.</li>
<li>WeTrade Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wetg#NASDAQ">WETG</a>) gained 50% to $3.36.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) climbed 33.6% to $13.70 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Biora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bior#NASDAQ">BIOR</a>) surged 32.2% to $1.39.</li>
<li>AdaptHealth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahco#NASDAQ">AHCO</a>) jumped 29.6% to $9.89 following fourth-quarter results.</li>
<li>Codexis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdxs#NASDAQ">CDXS</a>) rose 29% to $4.1283. Codexis entered into exclusive licensing agreement with Roche for double-stranded DNA Ligase.</li>
<li>Beam Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/beam#NASDAQ">BEAM</a>) gained 26.8% to $45.43 after the company reported fourth-quarter financial results.</li>
<li>BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) rose 26% to $3.14. Cantor Fitzgerald analyst Yi Fu Lee maintained BigBear.ai with an Overweight and maintained $3 price target.</li>
<li>5E Advanced Materials, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/feam#NASDAQ">FEAM</a>) gained 24.3% to $1.84.</li>
<li>Earlyworks Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elws#NASDAQ">ELWS</a>) gained 24.2% to $0.7321. Earlyworks was selected as a co-creation partner for MetaMe&reg; a meta-communication service utilizing cutting-edge technology from NTT DOCOMO, one of Japan&#39;s largest cell phone operators.</li>
<li>The Singing Machine Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mics#NASDAQ">MICS</a>) rose 24.1% to $0.9012.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) jumped 24% to $0.3299.</li>
<li>Ligand Pharmaceuticals Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgnd#NASDAQ">LGND</a>) gained 23% to $91.68 following upbeat quarterly earnings.</li>
<li>SoundHound AI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soun#NASDAQ">SOUN</a>) jumped 22.3% to $7.03 after gaining more than 46% on Monday.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) gained 21.3% to $5.80. Pyxis Oncology announced a $50 million private placement.</li>
<li>PubMatic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pubm#NASDAQ">PUBM</a>) shares climbed 20.8% to $20.01 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>) jumped 20.5% to $1.76.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) gained 20.4% to $13.63.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strl#NASDAQ">STRL</a>) jumped 19% to $107.00 after the company reported fourth-quarter financial results.</li>
<li>Denali Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dnli#NASDAQ">DNLI</a>) gained 17.6% to $19.87 following quarterly results.</li>
<li>National Vision Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eye#NASDAQ">EYE</a>) rose 17.6% to $23.48 following strong results.</li>
<li>Heidrick &amp; Struggles International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsii#NASDAQ">HSII</a>) gained 16.7% to $33.81 following strong results.</li>
<li>Ault Alliance, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ault#NASDAQ">AULT</a>) rose 15.8% to $0.4520. Ault Alliance announced record preliminary 2023 revenue of $153 million.</li>
<li>Portillo&#39;s Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptlo#NASDAQ">PTLO</a>) gained 15.6% to $15.90 following upbeat results.</li>
<li>Dorman Products, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dorm#NASDAQ">DORM</a>) climbed 11.5% to $92.67 following upbeat earnings.</li>
<li>Constellation Energy Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ceg#NASDAQ">CEG</a>) gained 9.7% to $146.27 following strong sales..</li>
<li>NovoCure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvcr#NASDAQ">NVCR</a>) gained 9.5% to $16.31.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) gained 9.5% to $85.14 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>) shares dipped 56.9% to $2.93 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) fell 55.8% to $1.2180. The stock continues to experience marked volatility after the company on Monday said it encountered an unexpected delay in its planned reverse stock split.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) fell 32.7% to $0.2878 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.</li>
<li>Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) fell 30.6% to $3.20 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.</li>
<li>Alpine 4 Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpp#NASDAQ">ALPP</a>) dipped 26% to $0.8799.</li>
<li>Stagwell Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stgw#NASDAQ">STGW</a>) fell 25.6% to $5.22 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Calidi Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NASDAQ">CLDI</a>) dipped 24.9% to $0.9084.</li>
<li>Clarivate Plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clvt#NYSE">CLVT</a>) fell 23.3% to $6.85 after the company reported fourth-quarter financial results and issued guidance.</li>
<li>Edgio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egio#NASDAQ">EGIO</a>) fell 21.5% to $0.2450. Edgio announced effectiveness of reverse stock split.</li>
<li>Telesis Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbio#NASDAQ">TBIO</a>) fell 21% to $0.5215 after tumbling 15% on Monday. Telesis Bio said it sees preliminary 2023 total consolidated revenue of $27.5 million.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) dipped 20.3% to $11.36.</li>
<li>Pineapple Energy Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pegy#NASDAQ">PEGY</a>) shares fell 19.6% to $0.0654. On Feb. 5. Pineapple Energy priced a $1 million registered direct offering of common stock.</li>
<li>The Aaron&#39;s Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aan#NYSE">AAN</a>) shares fell 16.7% to $8.71. Aaron&#39;s reported a loss for the fourth quarter, while sales missed estimates.</li>
<li>Perrigo Company plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/prgo#NYSE">PRGO</a>) fell 15.1% to $27.33 after the company reported fourth quarter financial results.</li>
<li>Intuitive Machines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lunr#NASDAQ">LUNR</a>) fell 10% to $5.64. Intuitive Machines said communications with moon lander Odysseus is expected to cease Tuesday morning, effectively ending mission 5 days after touchdown, Reuters reported.</li>
<li>Unity Software Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/u#NYSE">U</a>) fell 8.3% to $30.31 after the company reported mixed financial results for its fourth quarter. The company said it sees first-quarter strategic portfolio revenue in the range of $415 million to $420 million.</li>
<li>Primoris Services Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prim#NASDAQ">PRIM</a>) dipped 7.2% to $ 37.63 after the company reported mixed fourth quarter financial results.</li>
<li>LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) fell 6.9% to $31.90 following weak sales.</li>
<li>CarGurus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/carg#NASDAQ">CARG</a>) shares fell 4.2% to $22.89 after the company reported fourth-quarter financial results.</li>
<li>Workday, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wday#NASDAQ">WDAY</a>) shares declined 2.9% to $298.42 after the company reported fourth-quarter financial results, reiterated guidance and announced its intent to acquire HiredScore.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37328014/how-to-earn-500-a-month-from-ebay-stock-ahead-of-q4-earnings-report"> How To Earn $500 A Month From eBay Stock Ahead Of Q4 Earnings Report </a>

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Minerva Neurosciences Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) shares are trading lower after the FDA issued a Complete Response Letter (CRL) to the company&#8217;s marketing application for roluperidone for the treatment of negative symptoms in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/g37332988/minerva-neurosciences-receives-complete-response-letter-from-fda-for-new-drug-application-for-rolu" rel="noreferrer noopener">patients with schizophrenia</a>.
In the CRL, the FDA cited the following clinical deficiencies:
<ul>
<li>Although one study (MIN-101C03) demonstrated statistical significance on the primary efficacy endpoint, it is insufficient on its own to establish substantial evidence of effectiveness.</li>
<li>&nbsp;The application submission lacks data on concomitant antipsychotic administration.</li>
<li>&nbsp;The NDA submission lacks the data needed to establish that the change in negative symptoms of schizophrenia with roluperidone treatment was clinically meaningful.</li>
<li>&nbsp;The submitted safety database included an inadequate number of subjects exposed to roluperidone at the proposed dose (64 mg) for at least 12 months.</li>
<li>&nbsp;To address these deficiencies, the FDA stated that Minerva must submit at least one additional positive, adequate, and well-controlled study to support the safety and effectiveness of roluperidone for treating negative symptoms.&nbsp;</li>
<li>&nbsp;Minerva must also provide additional data to demonstrate the safety and efficacy of roluperidone co-administered with antipsychotic medications, to support that observed effect on negative symptoms with roluperidone treatment corresponds to a clinically meaningful change, and to demonstrate the long-term safety of the proposed dose.</li>
</ul>
&#8220;We believe that roluperidone is a safe and effective therapy for negative symptoms of schizophrenia, and we will review FDA&#8217;s feedback and consider our potential paths forward, including continuing to work closely with the FDA and providing any additional information as needed,&#8221; said Dr. Remy Luthringer, Executive Chairman and CEO of Minerva.
In addition to the clinical deficiencies, the FDA also provided comments on, among other items, clinical pharmacology, product quality, biopharmaceutics, and nonclinical issues.
Cash, cash equivalents, and restricted cash at December 31, 2023, were&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/g37256959/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2023-financial-results-and-business-u" rel="noreferrer noopener">approximately $41.0 million</a>.
Price Action:&nbsp;NERV shares are down 62.1% at $2.55 during the premarket session on the last check Tuesday.

Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) with a Neutral and maintains $11 price target.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $11 Price Target

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. </li>
<li>Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares moved upwards by 91.96% to $73.87. The company's market cap stands at $7.4 billion. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares moved upwards by 41.81% to $2.34. The company's market cap stands at $156.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares rose 33.24% to $1.4. The market value of their outstanding shares is at $38.0 million. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares increased by 31.4% to $4.21. The company's market cap stands at $293.6 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares moved upwards by 31.02% to $13.43. The company's market cap stands at $2.8 billion. As per the news, the Q4 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock decreased by 57.1% to $2.92 during Tuesday's regular session. The market value of their outstanding shares is at $20.4 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock declined by 32.77% to $0.29. The company's market cap stands at $24.4 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares decreased by 24.93% to $0.91. The market value of their outstanding shares is at $32.2 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock fell 21.22% to $0.52. The company's market cap stands at $15.5 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares decreased by 15.21% to $0.49. The company's market cap stands at $2.5 million. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) stock decreased by 14.15% to $17.64. The market value of their outstanding shares is at $714.2 million. The company's, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTMX

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SIBN

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Tuesday.
The Dow traded down 0.39% to 38,915.65 while the NASDAQ rose 0.15% to 15,999.50. The S&amp;P 500 also fell, dropping, 0.03% to 5,067.80.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37331804/wall-streets-most-accurate-analysts-views-on-3-risk-off-stocks-with-over-5-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Risk Off Stocks With Over 5% Dividend Yields </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Utilities shares rose by 1.5% on Tuesday.
In trading on Tuesday, energy shares fell by 0.5%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Macy&rsquo;s Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) reported mixed quarterly results and announced plans to close 150 stores.
The company reported fourth-quarter adjusted EPS of $2.45, beating the analyst consensus of $1.96. Quarterly revenue of $8.12 billion missed the analyst consensus of $8.15 billion. Sales fell 1.7% year over year.
Macy&rsquo;s announced a new strategy, &ldquo;A Bold New Chapter,&rdquo; designed to return the company to enterprise growth. The company plans to focus on Macy&rsquo;s resources by closing approximately 150 underproductive locations through 2026.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares shot up 195% to $44.47 after the company announced updated clinical data for both of its clinical programs.
Shares of Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) got a boost, surging 35% to $13.80 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.
Viking Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares were also up, gaining 100% to $76.92 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>) shares dropped 58% to $2.88 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
Shares of Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) were down 28% to $3.33 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.
NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) was down, falling 32% to $0.2901 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 1% to $78.35 while gold traded up 0.2% at $2,042.60.
Silver traded fell 0.2% to $22.485 on Tuesday while copper rose 0.5% to $3.8520.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.24%, London&rsquo;s FTSE 100 rose 0.04% while Spain&rsquo;s IBEX 35 Index fell 0.22% The German DAX gained 0.78% French CAC 40 rose 0.29% while Italy&rsquo;s FTSE MIB Index rose 0.48%.
Bank lending to households in the Eurozone rose by 0.3% year-over-year to EUR 6.870 trillion for January. The consumer confidence indicator in France declined to 89 in February versus around two-year high level of 91 in the prior month. The GfK Consumer Climate Indicator for Germany climbed to a reading of -29.0 heading into March compared to February&#39;s level of 29.6.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 0.01%, Hong Kong&rsquo;s Hang Seng Index climbing 0.94%, China&rsquo;s Shanghai Composite Index surging 1.29% and India&rsquo;s S&amp;P BSE Sensex gaining 0.4%.
Hong Kong recorded a trade surplus of $3.6 billion in January compared to a year-ago deficit of $25.4 billion. The annual inflation rate in Japan slowed to 2.2% in January compared to 2.6% in the earlier month.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. durable goods orders fell by 6.1% month-over-month in January compared to a 0.3% decline in December.
The FHFA house price index rose 0.1% in December following a 0.4% increase in November.
The S&amp;P CoreLogic Case-Shiller 20-city home price index climbed by 6.1% year-over-year in December.
The Dallas Fed general business activity index for Texas&rsquo; service sector rose to -3.9 in February from -9.3 in the previous month.
Now Read This: <a href="https://www.benzinga.com/news/24/02/37333478/roku-crocs-and-2-other-stocks-insiders-are-selling"> Roku, Crocs And 2 Other Stocks Insiders Are Selling </a>
&nbsp;

Crude Oil Gains 1%; Macy's Plans To Close 150 Stores

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.07% to 39,043.13 while the NASDAQ rose 0.31% to 16,026.43. The S&amp;P 500 also rose, gaining, 0.10% to 5,074.75.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37331804/wall-streets-most-accurate-analysts-views-on-3-risk-off-stocks-with-over-5-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Risk Off Stocks With Over 5% Dividend Yields </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Utilities shares rose by 0.7% on Tuesday.
In trading on Tuesday, health care shares fell by 0.3%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Lowe&rsquo;s Companies Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/low#NYSE">LOW</a>) posted better-than-expected fourth-quarter results.
Lowe&rsquo;s reported fourth-quarter FY23 sales of $18.60 billion, beating the analyst consensus estimate of $18.45 billion. EPS of $1.77 beat the consensus estimate of $1.68.
For FY24, Lowe&rsquo;s expects revenue of $84 billion-$85 billion (against the Street view of $85.61 billion) and adjusted EPS of $12.00 &ndash; $12.30 vs. consensus of $12.95. The company expects comparable sales to decline about 2% to 3% in FY24.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares shot up 138% to $36.00 after the company announced updated clinical data for both of its clinical programs.
Shares of Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) got a boost, surging 111% to $5.84. The stock continues to experience marked volatility after the company on Monday said it encountered an unexpected delay in its planned reverse stock split.
Viking Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares were also up, gaining 79% to $68.93 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>) shares dropped 58% to $2.84 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
Shares of Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) were down 35% to $2.9950 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.
NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) was down, falling 31% to $0.2930 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.6% to $78.01 while gold traded up 0.3% at $2,045.20.
Silver traded fell 0.6% to $22.65 on Tuesday while copper rose 0.3% to $3.8440.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.1%, London&rsquo;s FTSE 100 fell 0.1% while Spain&rsquo;s IBEX 35 Index fell 0.5% The German DAX gained 0.5% French CAC 40 rose 0.1% while Italy&rsquo;s FTSE MIB Index rose 0.1%.
Bank lending to households in the Eurozone rose by 0.3% year-over-year to EUR 6.870 trillion for January. The consumer confidence indicator in France declined to 89 in February versus around two-year high level of 91 in the prior month. The GfK Consumer Climate Indicator for Germany climbed to a reading of -29.0 heading into March compared to February&#39;s level of 29.6.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 0.01%, Hong Kong&rsquo;s Hang Seng Index climbing 0.94%, China&rsquo;s Shanghai Composite Index surging 1.29% and India&rsquo;s S&amp;P BSE Sensex gaining 0.4%.
Hong Kong recorded a trade surplus of $3.6 billion in January compared to a year-ago deficit of $25.4 billion. The annual inflation rate in Japan slowed to 2.2% in January compared to 2.6% in the earlier month.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. durable goods orders fell by 6.1% month-over-month in January compared to a 0.3% decline in December.
The FHFA house price index rose 0.1% in December following a 0.4% increase in November.
The S&amp;P CoreLogic Case-Shiller 20-city home price index climbed by 6.1% year-over-year in December.
Now Read This: <a href="https://www.benzinga.com/news/24/02/37333478/roku-crocs-and-2-other-stocks-insiders-are-selling"> Roku, Crocs And 2 Other Stocks Insiders Are Selling </a>

Nasdaq Rises 50 Points; Lowe's Earnings Top Views

Minerva Neurosciences Shares Resume Trade

Minerva Neurosciences Shares Halted On Circuit Breaker To The Downside, Stock Now Down -58.2%

WIIM

Minerva Neurosciences shares are trading lower after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

In the CRL, the FDA cited the following clinical deficiencies:
<ol>
<li>Although one study (MIN-101C03) demonstrated statistical significance on the primary efficacy endpoint, it is insufficient on its own to establish substantial evidence of effectiveness. &nbsp;</li>
<li>The NDA submission lacks data on concomitant antipsychotic administration. &nbsp;</li>
<li>The NDA submission lacks data needed to establish that the change in negative symptoms of schizophrenia with roluperidone treatment was clinically meaningful. &nbsp;</li>
<li>The submitted safety database included an inadequate number of subjects exposed to roluperidone at the proposed dose (64 mg) for at least 12 months.</li>
</ol>

Minerva Neurosciences Receives Complete Response Letter From FDA For New Drug Application For Roluperidone For Treatment Of Negative Symptoms In Patients With Schizophrenia Due To Clinical Deficiencies

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) reported its Q4 earnings results on Thursday, February 22, 2024 at 07:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Minerva Neurosciences missed estimated earnings by 35.23%, reporting an EPS of $-1.19 versus an estimate of $-0.88.
Revenue was down $0 from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.26 which was followed by a 0.38% drop in the share price the next day.

To track all earnings releases for Minerva Neurosciences <a href="https://www.benzinga.com/quote/NERV/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Minerva Neurosciences: Q4 Earnings Insights

Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.88) by 35.23 percent. This is a 5.56 percent increase over losses of $(1.26) per share from the same period last year.

Minerva Neurosciences Q4 EPS $(1.19) Misses $(0.88) Estimate; Cash, Cash Equivalents And Restricted Cash Were Approximately $41M

<h3>Gainers</h3>
<ul>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares rose 479.7% to $6.44 during Thursday's regular session. The company's market cap stands at $41.3 million. </li>
<li>NanoString Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTG#NASDAQ">NSTG</a>) stock moved upwards by 197.18% to $0.16. The market value of their outstanding shares is at $7.6 million. </li>
<li>Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) shares increased by 34.35% to $4.19. The market value of their outstanding shares is at $176.9 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 27.87% to $3.67. The company's market cap stands at $15.8 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 24.03% to $0.38. The company's market cap stands at $2.2 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) stock rose 23.93% to $1.45. The market value of their outstanding shares is at $31.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) stock fell 64.7% to $5.04 during Thursday's regular session. The market value of their outstanding shares is at $1.7 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) shares decreased by 31.2% to $0.25. The market value of their outstanding shares is at $3.0 million. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock declined by 24.67% to $0.51. The market value of their outstanding shares is at $2.3 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares fell 22.13% to $0.88. The market value of their outstanding shares is at $11.4 million. </li>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) shares decreased by 21.49% to $8.45. The market value of their outstanding shares is at $59.0 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares decreased by 21.06% to $0.57. The market value of their outstanding shares is at $274.1 million. The company's, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

CVKD

DYNT

FEMY

FHTX

HCTI

NSTG

SYRA

TENX

YTEN

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 70.0% to $0.94 during Monday's after-market session. The company's market cap stands at $8.0 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 17.57% to $0.36. The company's market cap stands at $5.4 million. </li>
<li>NanoString Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTG#NASDAQ">NSTG</a>) shares moved upwards by 16.61% to $0.12. The market value of their outstanding shares is at $5.7 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares moved upwards by 11.95% to $0.37. The market value of their outstanding shares is at $11.0 million. </li>
<li>Graphite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPH#NASDAQ">GRPH</a>) shares rose 11.78% to $2.94. The market value of their outstanding shares is at $171.1 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares increased by 7.79% to $2.42. The company's market cap stands at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) stock decreased by 8.0% to $0.64 during Monday's after-market session. The company's market cap stands at $2.0 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) stock decreased by 7.57% to $1.71. The company's market cap stands at $45.0 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) shares declined by 7.28% to $0.43. The company's market cap stands at $1.9 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 5.27% to $0.54. The company's market cap stands at $7.4 million. </li>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock declined by 4.82% to $10.27. The market value of their outstanding shares is at $71.8 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 4.69% to $3.05. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

BEAT

GRPH

OGEN

PXMD

REVB

STSS

THMO

XCUR

12 Health Care Stocks Moving In Monday's After-Market Session

Minerva falls as FDA rejects schizophrenia therapy

InvestorsObserver is giving Minerva Neurosciences Inc (NERV) an Analyst Rating Rank of 5, meaning NERV is ranked higher by analysts than 5% of stocks. The average price target for NERV is $11 and analystâ€&#x2122;s rate the stock as a Hold. Wall Street analysts are rating NERV a Hold today.  Find out what this means to you and get

Analyst Rating: Will Minerva Neurosciences Inc (NERV) Stock Do Better Than the Market?

Douglas Tsao, an analyst from H.C. Wainwright, maintained the Hold rating on Minerva Neurosciences (NERV – Research Report). The associated price t...

Hold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial Constraints

BBAI, CTMX and STRC among mid-day movers

These Healthcare stocks are trading higher:-Janux Therapeutics Inc (JANX) stock is trading at $46.54, a gain of $31.44, or 211.39%, on high volume.  Janux Therapeutics Inc gets a Sentiment Score of Neutral from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $26.67. Jan

Healthcare Stocks Making Moves Tuesday: JANX, VKTX, BIOR, CTMX, NERV, PRGO, CMAX, SIBN

Minerva Neurosciences Inc (NERV) is near the middle in its industry group according to InvestorsObserver. NERV gets an overall rating of 44. That means it scores higher than 44 percent of stocks. Minerva Neurosciences Inc gets a 38 rank in the Biotechnology industry. Biotechnology is number 15 out of 148 industries. NERV h

Should Biotechnology Stock Minerva Neurosciences Inc (NERV) Be in Your Portfolio Wednesday?

A rating of 57 puts Minerva Neurosciences Inc (NERV) near the top of the Healthcare sector according to InvestorsObserver.Minerva Neurosciences Inc's score of 57 means that it ranks higher than 57% of stocks in the sector. In addition, its overall score of 23 ranks it higher than 23% of all stocks. NERV has an Overall Scor

Will Minerva Neurosciences Inc (NERV) Beat the Rest of the Stocks in the Healthcare Sector?

Minerva Neurosciences Inc (NERV) has fallen Monday morning, with the stock decreasing -4.94% in pre-market trading to 2.5. NERV's short-term technical score of 8 indicates that the stock has traded less bullishly over the last month than 92% of stocks on the market. In the Biotechnology industry, which ranks 86 out of 146

Minerva Neurosciences Inc (NERV) Down 4.94% in Premarket Trading

Minerva Neurosciences GAAP EPS of -$1.13

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Minerva Neurosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/nerv-stock-quote/">NERV</a>) just reported results for the first quarter of 2024.<ul><li>Minerva Neurosciences reported earnings per share of -$1.13. This was above the analyst estimate for EPS of -$1.20.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/nerv-stock-earnings-minerva-neurosciences-for-q1-of-2024/">NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024

ACAD

ARIZ

ATCH

CMAX

KRTX

STRC

Press Releases

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

Financing

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Minerva Neurosciences Stock (NASDAQ:NERV), Short Interest Report

People Also Watch